-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FxwS5+lYQRoMAejRIJD8qvlaRYkyJIDFW8pEW+CjPCKq8fH8ysZHYDCWFFGk2MTc Pi7nAzovgv35jTdXACGoRQ== 0000905148-02-000406.txt : 20020414 0000905148-02-000406.hdr.sgml : 20020414 ACCESSION NUMBER: 0000905148-02-000406 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20020214 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: INTERNATIONAL BM BIOMEDICINE HOLDINGS INC CENTRAL INDEX KEY: 0001134905 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: NAUENSTRASSO 41 POSTFACH BASEL STREET 2: SWITZERLAND CH 4002 MAIL ADDRESS: STREET 1: NAUENSTRASSO 41 POSTFACH BASEL STREET 2: SWITZERLAND CH 4002 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: TELIK INC CENTRAL INDEX KEY: 0001109196 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930987903 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-60385 FILM NUMBER: 02548317 BUSINESS ADDRESS: STREET 1: 750 GATEWAY BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6502449303 MAIL ADDRESS: STREET 1: 750 GATEWAY BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 SC 13G/A 1 efc2-0166sc13ga.txt ================================= OMB APPROVAL ================================= ================================= OMB Number: 3235-0145 ================================= ================================= Expires: October 31, 2002 ================================= ================================= Estimated average burden hours per response. . . 14.9 ================================= UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Telik, Inc. - ------------------------------------------------------------------------------- (Name of Issuer) Common Stock - ------------------------------------------------------------------------------- (Title of Class of Securities) 87959M 10 9 - ------------------------------------------------------------------------------- (CUSIP Number) December 31, 2001 - ------------------------------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. ........... 87959M 10 9............................ - ------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). International BM Biomedicine Holdings AG - ------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) ........................................................... (b) ........................................................... 3. SEC Use Only .................................................................. 4. Citizenship or Place of Organization ..... Basel, Switzerland..... - ------------------------------------------------------------------------------- Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power ................... 1,481,607................... 6. Shared Voting Power ...............None........................... 7. Sole Dispositive Power.............1,481,607...................... 8. Shared Dispositive Power ..........None .......................... 9. Aggregate Amount Beneficially Owned by Each Reporting Person...............1,481,607.................... 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)....................... - ------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row (9) .........5.33%.. - ------------------------------------------------------------------------------- 12. Type of Reporting Person (See Instructions) ...........................................CO.................................. - ------------------------------------------------------------------------------- Item 1. (a) Name of Issuer: Telik, Inc. (b) Address of Issuer's Principal Executive Offices 750 Gateway Boulevard, South San Francisco, CA 94080 Item 2. (a) Name of Person Filing: International BM Biomedicine Holdings AG (b) Address of Principal Business Office or, if none, Residence Nauenstrasse 41, P.O. Box 4002, Basel, Switzerland (c) Citizenship: Switzerland (d) Title of Class of Securities: Common Stock (e) CUSIP Number 87959M 10 9 Item 3. If this statement is filed pursuant toss.ss.240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). (e) [ ] An investment adviser in accordance withss.240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F); (g) [ ] A parent holding company or control person in accordance with ss. 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] Group, in accordance withss.240.13d-1(b)(1)(ii)(J). Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: ________1,481,607________________. (b) Percent of class: 5.33% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote ______1,481,607. (ii) Shared power to vote or to direct the vote none. (iii) Sole power to dispose or to direct the disposition of 1,481,607. (iv) Shared power to dispose or to direct the disposition of none. Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ]. Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not Applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Not Applicable Item 8. Identification and Classification of Members of the Group Not Applicable Item 9. Notice of Dissolution of Group Not Applicable Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 14, 2002 -------------------------------- Date /s/ Dr. Gaudenz I. Staehelin -------------------------------- Signature Dr. Gaudenz I. Staehelin/Vice Chairman -------------------------------- Name/Title /s/ Patrick Weber -------------------------------- Signature Patrick Weber/CEO -------------------------------- Name/Title -----END PRIVACY-ENHANCED MESSAGE-----